I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 30% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 30% ± 13% |
Insufficient scRNA-seq data for expression of SLCO1B3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 5576.38 | 226 / 226 | 53% | 11.33 | 216 / 406 |
| intestine | 28% | 15.93 | 272 / 966 | 42% | 2.91 | 221 / 527 |
| esophagus | 13% | 17.93 | 194 / 1445 | 48% | 3.71 | 87 / 183 |
| prostate | 34% | 39.94 | 84 / 245 | 22% | 1.34 | 112 / 502 |
| pancreas | 14% | 30.15 | 45 / 328 | 30% | 1.60 | 54 / 178 |
| stomach | 14% | 15.52 | 51 / 359 | 29% | 1.95 | 83 / 286 |
| lung | 10% | 4.42 | 56 / 578 | 31% | 2.33 | 353 / 1155 |
| bladder | 5% | 3.00 | 1 / 21 | 27% | 1.94 | 137 / 504 |
| thymus | 32% | 18.61 | 206 / 653 | 0% | 0.00 | 1 / 605 |
| uterus | 8% | 21.09 | 13 / 170 | 19% | 1.81 | 87 / 459 |
| ovary | 6% | 1.67 | 11 / 180 | 8% | 0.38 | 33 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 9% | 0.27 | 4 / 45 |
| breast | 5% | 1.81 | 21 / 459 | 1% | 0.05 | 13 / 1118 |
| adipose | 5% | 2.07 | 56 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 3% | 12.11 | 8 / 241 | 0% | 0 | 0 / 0 |
| adrenal gland | 3% | 0.79 | 7 / 258 | 0% | 0 | 0 / 230 |
| blood vessel | 3% | 1.14 | 35 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 2% | 1.34 | 22 / 929 | 0% | 0 | 0 / 0 |
| skin | 2% | 0.65 | 30 / 1809 | 0% | 0.01 | 2 / 472 |
| kidney | 1% | 1.70 | 1 / 89 | 1% | 0.03 | 7 / 901 |
| brain | 1% | 0.54 | 33 / 2642 | 0% | 0 | 0 / 705 |
| muscle | 0% | 0.08 | 3 / 803 | 0% | 0 | 0 / 0 |
| heart | 0% | 0.05 | 1 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0015721 | Biological process | bile acid and bile salt transport |
| GO_0006811 | Biological process | monoatomic ion transport |
| GO_0043252 | Biological process | sodium-independent organic anion transport |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0042167 | Biological process | heme catabolic process |
| GO_0015711 | Biological process | organic anion transport |
| GO_0055085 | Biological process | transmembrane transport |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0009925 | Cellular component | basal plasma membrane |
| GO_0016323 | Cellular component | basolateral plasma membrane |
| GO_0015125 | Molecular function | bile acid transmembrane transporter activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0008514 | Molecular function | organic anion transmembrane transporter activity |
| GO_0015347 | Molecular function | sodium-independent organic anion transmembrane transporter activity |
| Gene name | SLCO1B3 |
| Protein name | Solute carrier organic anion transporter family member 1B3 (Liver-specific organic anion transporter 2) (LST-2) (OATP1B3) (Organic anion transporter 8) (Organic anion-transporting polypeptide 8) (OATP-8) (Solute carrier family 21 member 8) Solute carrier organic anion transporter family, member 1B3 Solute carrier organic anion transporter family member |
| Synonyms | LST3 SLC21A8 OATP-8 HBLRR LST2 OATP1B3 LST-3TM13 OATP8 LST-2 |
| Description | FUNCTION: Mediates the Na(+)-independent uptake of organic anions . Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (17-beta-glucuronosyl estradiol, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate), as well as eicosanoid leukotriene C4, prostaglandin E2 and L-thyroxine (T4) . Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions . Shows a pH-sensitive substrate specificity towards sulfated steroids, taurocholate and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment . Involved in the clearance of bile acids and organic anions from the liver . Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop . Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition . May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins) such as pitavastatin, a clinically important class of hypolipidemic drugs . May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drugs methotrexate and paclitaxel . May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver . . |
| Accessions | Q0VGL9 Q9NPD5 A0A1J1EWS0 ENST00000261196.6 [Q9NPD5-1] H0YGG9 ENST00000540853.5 ENST00000381545.8 [Q9NPD5-1] Q6NSD0 F5H8K0 ENST00000544370.1 |
